The "Neuroendocrine Tumor Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2029" report has been added to ResearchAndMarkets.com's offering.
Neuroendocrine tumors can be benign or malignant. This condition rarely shows any symptoms and occurs usually in the pancreas, lungs, gastrointestinal tracts, and other organs of the body. According to the World Health Organization, the incidence of malignant neuroendocrine tumors is 0.2 per 100,000 people. The increased incidence of neuroendocrine tumors (NET) is constantly driving the need for research and therapeutic options. Additionally, there is a keen focus on developing diagnostic devices and technologies. R&D efforts of market players are, therefore, accelerating the market growth over the forecast period of 2019 to 2029. The impact of covid 19 has been really significant impact on the healthcare segment. The pandemic delayed diagnosis and non-emergency and elective surgeries, this led to an increasing queue of patients waiting to avail healthcare solutions. The report details the impact of covid 19 on the NET market in terms of market dynamics and revenues.
With respect to diagnosis R&D efforts have to novel techniques such as RF ablation technique, Ga labeled radionucleotide therapies. NET-01 chemotherapy for pancreatic tumors, RAD 001 to treat advanced midgut NETs are few examples of therapy techniques that are in the clinical trial stage. Cancer research has been one of the segments that has attracted investment in R&D for the longest time. Apart from research foundations, governments across several countries have been active in cancer research and funding. For instance, in January 2021 The Neuroendocrine Tumor Research Foundation (NETRF) awarded $2.62 million in grants to advanced research focusing on novel treatments for neuroendocrine tumors. In the past 15 years, NETRF has alone invested $30 million on research.
Targeted drug therapy for NET included molecules such as Everolimus and Sunitinib. The targeted therapies are in greater demand as they are efficient in impeding the growth of cancer by targeting the specified molecules that are involved in the growth of cancer. The key advantage of targeted drug therapies is lesser side effects in comparison to chemotherapy. However, some patients are immune to radiation therapy and surgeries, therefore Somatostatin analogues such as Lu-Dotatate and Octreotide remain as an alternative therapy in this case.
The incidence rate in the U.S. for gastrointestinal neuroendocrine neoplasms was about 1.4 cases per 100,000. The healthcare infrastructure in terms of diagnostic centers and drug clearance process through USFDA is very efficient even in case of asymptomatic NET. The rising incidence rate for NET in Europe especially in case of pancreatic NET has a significant impact on the NET drug market. The European Medical Agency provides a supportive regulatory environment. In case of Asia Pacific, the incident rate for NET was 1.5 per 100,000 people. The healthcare infrastructure in APAC is emerging. There has been a significant increase in cancer specialized diagnostic centers and emerging treatment options are expected to boost the NET drugs market during the forecast period of 2021 to 2029.
Advanced Accelerator Applications
Progenics Pharmaceuticals Inc.
Dauntless Pharmaceuticals Inc.
Hutchinson Medipharma Limited
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Neuroendocrine Tumor Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Neuroendocrine Tumor Epidemiology Data (Prevalence & Incidence)
3.6. Attractive Investment Proposition, by Geography
3.7. Top 3 Countries: Global Neuroendocrine Tumor Treatment Market, 2019-2029 (US$ Mn)
3.8. Competitive Landscape: Global Neuroendocrine Tumor Treatment Market, by Key Players, 2019-2029(US$ Mn)
Chapter 4. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019-2029 (US$ Mn)
4.2. Attractive Investment Proposition: Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2019
4.3. mTOR protein inhibitors (Everolimus)
4.4. Tyrosine kinase 3 inhibitors (Sunitinib)
4.5. Somatostatin receptor antagonists (Lu-Dotatate)
4.6. Growth hormone releasing factor antagonists (Lanreotide)
4.7. Somatostatin receptor agonists (Octreotide)
4.8. Pipeline Analysis
4.8.1. Phase III Drugs
22.214.171.124. Fotemustine and Ipilimumab
126.96.36.199. 177Lu-edotreotide PRRT
4.8.2. Tabular Representation of Phase II and I Drugs
Chapter 5. Global Neuroendocrine Tumor Treatment Market, by Geography, 2019-2029(US$ Mn)
5.2. North America Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.3. Europe Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.4. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.5. Latin America Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
5.6. Middle East & Africa Neuroendocrine Tumor Treatment Market Analysis, 2019-2029
Chapter 6. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/pa53m1
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005391/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900